FR2475901A1 - Procede de production d'interferon - Google Patents
Procede de production d'interferon Download PDFInfo
- Publication number
- FR2475901A1 FR2475901A1 FR8024833A FR8024833A FR2475901A1 FR 2475901 A1 FR2475901 A1 FR 2475901A1 FR 8024833 A FR8024833 A FR 8024833A FR 8024833 A FR8024833 A FR 8024833A FR 2475901 A1 FR2475901 A1 FR 2475901A1
- Authority
- FR
- France
- Prior art keywords
- interferon
- mrna
- cells
- dna
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 230000016396 cytokine production Effects 0.000 title description 3
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 133
- 102000014150 Interferons Human genes 0.000 claims abstract description 117
- 108010050904 Interferons Proteins 0.000 claims abstract description 117
- 229940079322 interferon Drugs 0.000 claims abstract description 115
- 210000004027 cell Anatomy 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000013598 vector Substances 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 210000005260 human cell Anatomy 0.000 claims abstract description 17
- 238000010367 cloning Methods 0.000 claims abstract description 8
- 239000000411 inducer Substances 0.000 claims abstract description 7
- 238000000746 purification Methods 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 4
- 239000002799 interferon inducing agent Substances 0.000 claims abstract description 4
- 108020004414 DNA Proteins 0.000 claims description 93
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 34
- 239000000523 sample Substances 0.000 claims description 27
- 239000002299 complementary DNA Substances 0.000 claims description 26
- 108020004635 Complementary DNA Proteins 0.000 claims description 23
- 239000013612 plasmid Substances 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 230000001939 inductive effect Effects 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 238000009396 hybridization Methods 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 230000003328 fibroblastic effect Effects 0.000 claims description 4
- 210000003953 foreskin Anatomy 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 101000757165 Mus musculus Aminopeptidase N Proteins 0.000 claims 1
- 230000014616 translation Effects 0.000 description 15
- 238000013519 translation Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 210000000287 oocyte Anatomy 0.000 description 11
- 239000001913 cellulose Substances 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 210000001995 reticulocyte Anatomy 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000001064 anti-interferon Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108010067304 (2'-5')oligo-isoadenylate synthetase Proteins 0.000 description 1
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- LMWMTSCFTPQVCJ-UHFFFAOYSA-N 2-methylphenol;phenol Chemical compound OC1=CC=CC=C1.CC1=CC=CC=C1O LMWMTSCFTPQVCJ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101000972324 Cynodon dactylon Leaf protein Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710149086 Nuclease S1 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001957 sucroglyceride Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL58765A IL58765A (en) | 1979-11-21 | 1979-11-21 | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2475901A1 true FR2475901A1 (fr) | 1981-08-21 |
| FR2475901B1 FR2475901B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1985-02-15 |
Family
ID=11051449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8024833A Granted FR2475901A1 (fr) | 1979-11-21 | 1980-11-21 | Procede de production d'interferon |
Country Status (9)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2481316A1 (fr) * | 1980-02-06 | 1981-10-30 | Searle & Co | Technique a adn de recombinant pour la preparation d'une proteine ressemblant a l'interferon humain |
| FR2490675A1 (fr) * | 1980-09-25 | 1982-03-26 | Genentech Inc | Production microbienne d'interferon de fibroplaste humain |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56131598A (en) * | 1980-03-19 | 1981-10-15 | Japan Found Cancer | Novel recombinant plasmid having gene of human fibroblastic interferon messenger rna |
| US5510472A (en) * | 1979-11-21 | 1996-04-23 | Yeda Research And Development Co. Ltd. | Production of recombinant human interferon-beta2 |
| US5554513A (en) * | 1979-11-21 | 1996-09-10 | Yeda Research & Development Co. Ltd. | Production of recombinant human interferon-beta2 |
| DE3005897A1 (de) * | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
| DE3005843A1 (de) * | 1980-02-16 | 1981-09-10 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus |
| NZ196706A (en) | 1980-04-03 | 1988-01-08 | Biogen Nv | Dna sequences, recombinant dna molecules and processes for producing fibroblast interferon-like polypeptides; pharmaceutical and veterinary compositions |
| DE3176011D1 (en) * | 1980-06-12 | 1987-04-23 | Japan Found Cancer | Plasmid |
| US5582824A (en) * | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
| AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| JPS58110548A (ja) * | 1981-12-24 | 1983-07-01 | Asahi Chem Ind Co Ltd | 新規な生理活性ペプチド |
| IE54592B1 (en) * | 1982-03-08 | 1989-12-06 | Genentech Inc | Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby |
| US6432677B1 (en) | 1982-03-08 | 2002-08-13 | Genentech, Inc. | Non-human animal interferons |
| US5827694A (en) * | 1982-03-08 | 1998-10-27 | Genentech, Inc. | DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| DE3220116A1 (de) * | 1982-05-28 | 1983-12-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung |
| US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US5831023A (en) * | 1982-11-01 | 1998-11-03 | Genentech, Inc. | Recombinant animal interferon polypeptides |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| EP0569687B1 (en) * | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
| US5998578A (en) * | 1984-05-18 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Biologically active fragments of IL-1β |
| US5122459A (en) * | 1984-12-31 | 1992-06-16 | Immunex Corporation | Gene encoding biologically active human interleukin 1 |
| EP0218700A4 (en) * | 1985-04-23 | 1988-09-19 | Medical Biology Inst | IDENTIFICATION OF AN IgE BINDING PROTEIN BY MOLECULAR CLONING. |
| DE3683186D1 (de) * | 1985-04-25 | 1992-02-13 | Hoffmann La Roche | Rekombinantes humaninterleukin-1. |
| EP0645452A1 (en) * | 1985-10-14 | 1995-03-29 | Yeda Research And Development Co. Ltd. | Human interferon-beta 2A and interfeon-beta 2B, vectors containing genes coding for said interferons, cell lines producing same and use of said interferons as pharmaceuticals |
| US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| IE67035B1 (en) * | 1986-07-08 | 1996-02-21 | Genetics Inst | Production and use of non-glycosylated IL-6 |
| US6284237B1 (en) | 1986-07-08 | 2001-09-04 | Steven C. Clark | Methods of treatment using IL-6 |
| EP0585957A1 (en) * | 1986-08-06 | 1994-03-09 | Ajinomoto Co., Inc. | Recombinant B-cell differentiation factor |
| US4939093A (en) * | 1987-02-02 | 1990-07-03 | Cetus Corporation | Human IL-2 like polypeptides, DNA sequences and recombinant DNA molecules therefore and methods for the production and use thereof |
| US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
| IL88375A (en) * | 1988-11-14 | 1995-07-31 | Yeda Res & Dev | Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method |
| US5338834A (en) * | 1993-01-26 | 1994-08-16 | Allelix Biopharmaceuticals Inc. | Ultrapure human interleukin-6 |
| US20050002902A1 (en) * | 1995-12-28 | 2005-01-06 | Liming Yu | Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US20030026779A1 (en) * | 1999-10-15 | 2003-02-06 | Liming Yu | Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc |
| ES2624547T3 (es) * | 2001-11-14 | 2017-07-14 | Janssen Biotech, Inc. | Anticuerpos anti il 6, composiciones, métodos y usos |
| US20050100550A1 (en) * | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
| NZ586034A (en) | 2004-02-02 | 2011-10-28 | Ambrx Inc | Modified human growth hormone polypeptides and their uses |
| PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| AU2008254578B2 (en) * | 2007-05-21 | 2013-06-06 | Alderbio Holdings Llc | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| HUE043782T2 (hu) * | 2007-05-21 | 2019-09-30 | Alderbio Holdings Llc | IL-6 elleni antitestek és alkalmazásuk |
| US8062864B2 (en) * | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| US8777182B2 (en) | 2008-05-20 | 2014-07-15 | Grinon Industries | Fluid transfer assembly and methods of fluid transfer |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| WO2011066378A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat thrombosis |
| CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2321298A1 (fr) * | 1975-08-01 | 1977-03-18 | Anvar | Procede de preparation de produits a activite interferon |
| WO1980002229A1 (en) * | 1979-04-20 | 1980-10-30 | Benzon As Alfred | Interferon proteins and method of producing same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| NZ187300A (en) * | 1977-05-27 | 1982-08-17 | Univ California | Dna transfer vector and micro-organism modified to contain a nucleotide sequence equivalent to the gene of a higher organism |
| JPS5663996A (en) * | 1979-10-30 | 1981-05-30 | Japan Found Cancer | Novel recombinant having gene complementary to human interferon messenger rna |
| US5326859A (en) * | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US4262090A (en) * | 1979-06-04 | 1981-04-14 | Cetus Corporation | Interferon production |
| US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
| JPS5655731A (en) * | 1979-10-11 | 1981-05-16 | Ogura Clutch Co Ltd | Clutch/brake device |
| NL7907791A (nl) * | 1979-10-23 | 1981-04-27 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
| NZ196706A (en) * | 1980-04-03 | 1988-01-08 | Biogen Nv | Dna sequences, recombinant dna molecules and processes for producing fibroblast interferon-like polypeptides; pharmaceutical and veterinary compositions |
| EP0041767B1 (en) * | 1980-06-06 | 1993-03-03 | Biogen, Inc. | Improved vectors and methods for making such vectors and for expressing cloned genes |
-
1979
- 1979-11-21 IL IL58765A patent/IL58765A/xx unknown
-
1980
- 1980-11-14 SE SE8007998A patent/SE461223C/sv not_active IP Right Cessation
- 1980-11-19 GB GB8037067A patent/GB2063882B/en not_active Expired
- 1980-11-20 US US06/208,925 patent/US5468607A/en not_active Expired - Lifetime
- 1980-11-21 CH CH3224/93A patent/CH684892A5/de not_active IP Right Cessation
- 1980-11-21 IT IT26172/80A patent/IT1194820B/it active
- 1980-11-21 FR FR8024833A patent/FR2475901A1/fr active Granted
- 1980-11-21 DE DE19803043981 patent/DE3043981A1/de active Granted
- 1980-11-21 DE DE3051086A patent/DE3051086C2/de not_active Expired - Lifetime
- 1980-11-21 CH CH8627/80A patent/CH664967A5/de not_active IP Right Cessation
- 1980-11-21 JP JP55164482A patent/JP2555279B2/ja not_active Expired - Lifetime
-
1982
- 1982-09-28 US US06/425,934 patent/US5541312A/en not_active Expired - Lifetime
- 1982-09-28 US US06/425,933 patent/US5468609A/en not_active Expired - Lifetime
- 1982-09-28 US US06/425,935 patent/US5468608A/en not_active Expired - Lifetime
-
1986
- 1986-07-17 SE SE8603145A patent/SE469660B/sv not_active IP Right Cessation
-
1987
- 1987-06-24 JP JP62157455A patent/JP2548201B2/ja not_active Expired - Lifetime
-
1989
- 1989-04-13 JP JP1094314A patent/JPH02211879A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2321298A1 (fr) * | 1975-08-01 | 1977-03-18 | Anvar | Procede de preparation de produits a activite interferon |
| WO1980002229A1 (en) * | 1979-04-20 | 1980-10-30 | Benzon As Alfred | Interferon proteins and method of producing same |
Non-Patent Citations (3)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 91, no. 13, 24 septembre 1979, réf.: 106454v, page 461 (COLUMBUS, OHIO, US) & Eur. J. Biochem. 1979, 98(1), 1-8 (Eng.) J. WEISSENBACH et al.: "Identification of the translation products of human fibroblast interferon mRNA in reticulocyte lysates" * |
| CHEMICAL ABSTRACTS, vol. 91, no.15, 8 octobre 1979, réf.: 122094h, page 475 (COLUMBUS, OHIO, US) & J. Gen. Virol. 1979, 44(1), 231-4 (Eng.) J. MORSER et al.: "Characterization of interferon messenger RNA from human lymphoblastoid cells" * |
| CHEMICAL ABSTRACTS, vol. 92, no. 11, 17 mars 1980 réf.: 90662u, page 281 (COLUMBUS, OHIO, US) & Proc. Jpn. Acad., Ser. B 1979, 55(9), 464-9 (Eng.), T. TANIGUCHI et al.: "Construction and identification of a bacterial plasmid containing the human fibroblast interferon gene sequence" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2481316A1 (fr) * | 1980-02-06 | 1981-10-30 | Searle & Co | Technique a adn de recombinant pour la preparation d'une proteine ressemblant a l'interferon humain |
| FR2490675A1 (fr) * | 1980-09-25 | 1982-03-26 | Genentech Inc | Production microbienne d'interferon de fibroplaste humain |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2548201B2 (ja) | 1996-10-30 |
| FR2475901B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1985-02-15 |
| CH684892A5 (de) | 1995-01-31 |
| SE469660B (sv) | 1993-08-16 |
| US5541312A (en) | 1996-07-30 |
| SE461223C (sv) | 1997-02-02 |
| SE8007998L (sv) | 1981-05-22 |
| SE8603145L (sv) | 1986-07-17 |
| JP2555279B2 (ja) | 1996-11-20 |
| GB2063882A (en) | 1981-06-10 |
| JPS63164896A (ja) | 1988-07-08 |
| DE3051086C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-11-05 |
| CH664967A5 (de) | 1988-04-15 |
| IL58765A0 (en) | 1980-02-29 |
| GB2063882B (en) | 1984-05-31 |
| JPH02211879A (ja) | 1990-08-23 |
| IT8026172A0 (it) | 1980-11-21 |
| DE3043981C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-11-30 |
| JPS5685296A (en) | 1981-07-11 |
| IT1194820B (it) | 1988-09-28 |
| DE3043981A1 (de) | 1981-10-01 |
| IL58765A (en) | 1986-09-30 |
| US5468608A (en) | 1995-11-21 |
| US5468609A (en) | 1995-11-21 |
| US5468607A (en) | 1995-11-21 |
| SE8603145D0 (sv) | 1986-07-17 |
| SE461223B (sv) | 1990-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2475901A1 (fr) | Procede de production d'interferon | |
| Singh et al. | Analysis of the genomic L RNA segment from lymphocytic choriomeningitis virus | |
| Demuth et al. | Cloning and structural characterization of a human non‐erythroid band 3‐like protein. | |
| Willumsen et al. | Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. | |
| FR2514783A1 (fr) | Interferon immunitaire humain | |
| Liu et al. | The HumanNTTGene: identification of a novel 17-kb noncoding nuclear RNA expressed in activated CD4+ T cells | |
| EP1916304B1 (fr) | Polypeptides antigéniques associés à la sclérose en plaques et utilisations | |
| FR2486098A1 (fr) | Interferons et procede pour leur preparation | |
| EP0506574B1 (fr) | Protéine à activité de type cytokine, ADN recombinant codant pour cette protéine, cellules et microorganismes transformés | |
| JPS60252496A (ja) | 新規なヒト生理活性ポリペプチド | |
| FR2677372A1 (fr) | Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques. | |
| Deen et al. | Murine mammary tumor virus pol-related sequences in human DNA: characterization and sequence comparison with the complete murine mammary tumor virus pol gene | |
| JP2000060577A (ja) | 成熟ヒトインタ―ロイキン１タンパク質 | |
| JPH04507044A (ja) | タンパク質ホルモン形成の抑制用の組成物およびその使用法 | |
| JPH06510790A (ja) | 分泌Ｍａｃ−２結合糖タンパク質 | |
| FR2509614A1 (fr) | Production d'interferon | |
| JPS59135892A (ja) | シグナルアミノ酸配列をコードするｄｎａ | |
| Bell et al. | The N-terminus of PE2 in Sindbis virus-infected cells | |
| FR2481316A1 (fr) | Technique a adn de recombinant pour la preparation d'une proteine ressemblant a l'interferon humain | |
| JPH1070986A (ja) | ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体 | |
| CN114599672A (zh) | 一种角蛋白bd-11、制法和其药物组合物与用途 | |
| Pestka | Production and analysis of proteins by recombinant DNA technology | |
| EP0731168A1 (fr) | Virus MSRV-1 et agent pathogène et/ou infectant MSRV-2 associés à la polyarthrite rhumatoide | |
| Ikawa et al. | RNA sequences and proteins specific to Friend strain of spleen focus-forming virus | |
| Near et al. | Immunoglobulin. mu.-and. gamma.-ribonucleic acid sequences in thymocytes and splenocytes from normal and hyperimmune mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property |